Robert J Prosser1, Bruce C Carleton, M Anne Smith. 1. Pharmaceutical Outcomes Programme, Children's and Women's Health Centre of British Columbia, University of British Columbia, 4480 Oak Street, Room B404, Vancouver, BC, Canada V6H 3V4.
Abstract
OBJECTIVE: To develop a parsimonious model of the respiratory patient population in British Columbia (BC), Canada through latent class modelling (LCM), using administrative data records and to assess conventional case definitions for asthma in relation to model-based case selection. DATA SOURCES: 1996-2001 data from linked provincial databases containing fee-for-service physician billing records, hospital inpatient separation abstracts, and prescription drug purchase records for 1.9 million BC respiratory patients. STUDY DESIGN: This is a retrospective methodological/descriptive study that assesses case definitions for asthma in terms of sensitivity and specificity using a model fitted to seven physician, hospital and medication utilization markers in place of a conventional gold standard. DATA COLLECTION: We computed values of the treatment markers for each of the 5 years for each patient aged 5-55 years who had had at least one occurrence of a respiratory diagnosis code. PRINCIPAL FINDINGS: The marker for prescription of short-acting beta agonists (SABAs) consistently had the highest sensitivity. Markers' specificities ranged from 0.97 to 1.0. The conventional case definitions' sensitivities were 0.41-0.87; specificities ranged from 0.98 to 0.997. Model-based estimates of asthma prevalence increased from 827/10,000 in 1996 to 992/10,000 in 2001. Conventional case definitions' estimates were consistently lower. CONCLUSIONS: The linkage between utilization and case status is more complex than conventional case definitions allow for. LCM-based case classification was consistent over time and tends to lead to larger prevalence estimates than conventional definitions. The estimated increases in asthma prevalence are reliable. LCM provides health services planners with a useful probability-based approach for developing and assessing case definitions and estimating case prevalence.
OBJECTIVE: To develop a parsimonious model of the respiratory patient population in British Columbia (BC), Canada through latent class modelling (LCM), using administrative data records and to assess conventional case definitions for asthma in relation to model-based case selection. DATA SOURCES: 1996-2001 data from linked provincial databases containing fee-for-service physician billing records, hospital inpatient separation abstracts, and prescription drug purchase records for 1.9 million BC respiratory patients. STUDY DESIGN: This is a retrospective methodological/descriptive study that assesses case definitions for asthma in terms of sensitivity and specificity using a model fitted to seven physician, hospital and medication utilization markers in place of a conventional gold standard. DATA COLLECTION: We computed values of the treatment markers for each of the 5 years for each patient aged 5-55 years who had had at least one occurrence of a respiratory diagnosis code. PRINCIPAL FINDINGS: The marker for prescription of short-acting beta agonists (SABAs) consistently had the highest sensitivity. Markers' specificities ranged from 0.97 to 1.0. The conventional case definitions' sensitivities were 0.41-0.87; specificities ranged from 0.98 to 0.997. Model-based estimates of asthma prevalence increased from 827/10,000 in 1996 to 992/10,000 in 2001. Conventional case definitions' estimates were consistently lower. CONCLUSIONS: The linkage between utilization and case status is more complex than conventional case definitions allow for. LCM-based case classification was consistent over time and tends to lead to larger prevalence estimates than conventional definitions. The estimated increases in asthma prevalence are reliable. LCM provides health services planners with a useful probability-based approach for developing and assessing case definitions and estimating case prevalence.
Authors: Mohsen Sadatsafavi; Larry Lynd; Carlo Marra; Bruce Carleton; Wan C Tan; Sean Sullivan; J Mark Fitzgerald Journal: Can Respir J Date: 2010 Mar-Apr Impact factor: 2.409
Authors: Sasha Bernatsky; Audrey Smargiassi; Markey Johnson; Gilaad G Kaplan; Cheryl Barnabe; Larry Svenson; Allan Brand; Stefania Bertazzon; Marie Hudson; Ann E Clarke; Paul R Fortin; Steven Edworthy; Patrick Bélisle; Lawrence Joseph Journal: Environ Res Date: 2015-05-16 Impact factor: 6.498
Authors: S Bernatsky; L Lix; J G Hanly; M Hudson; E Badley; C Peschken; C A Pineau; A E Clarke; P R Fortin; M Smith; P Bélisle; C Lagace; L Bergeron; L Joseph Journal: Rheumatol Int Date: 2010-07-28 Impact factor: 2.631
Authors: Lisa M Lix; Marina S Yogendran; Souradet Y Shaw; Laura E Targownick; Jennifer Jones; Osama Bataineh Journal: BMC Health Serv Res Date: 2010-02-01 Impact factor: 2.655
Authors: Mohsen Sadatsafavi; Amir Khakban; Hamid Tavakoli; Solmaz Ehteshami-Afshar; Larry D Lynd; J Mark FitzGerald Journal: Respir Res Date: 2021-04-09